BlossomHill Therapeutics, Inc. BLSM
Set alert
12.41 USD -1.34 -9.72%
As of Nov 2, 11:51 AM ET
12.28 Day range 14.23
12.28 52-week range 27.99
- YTD
- -22.41%
- 1 year
- -22.41%
- Open
- 14.23
- Prev close
- 13.75
- Mkt cap
- 394.57M
- Vol
- 56.64K
- Avg vol
- 226.76K
- EPS
- -4.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.28
- High
- 14.23
Financials — quick view
BLSM Revenue — quarterly 0
BLSM Net income — quarterly -23.76M
BLSM EPS — quarterly -8.75
News
- BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
- BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation
- BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
- BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
- BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why
- BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027
- BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
- Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
- Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
- Earnings Scheduled For September 18, 2026
Your note
Sign in to keep a note on BLSM — it syncs with the Stock Master app.